Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 21.1% in December

Lucid Diagnostics Inc. (NASDAQ:LUCD) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 332,700 shares, a decrease of 21.1% from the November 30th total of 421,800 shares. Based on an average daily volume of 432,600 shares, the short-interest ratio is currently 0.8 days. Approximately 1.4% of the company’s stock are short sold.

Wall Street Analyst Weigh In

LUCD has been the topic of several analyst reports. Cantor Fitzgerald dropped their price objective on Lucid Diagnostics from $3.00 to $2.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a research note on Thursday, November 14th. Canaccord Genuity Group restated a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Finally, Ascendiant Capital Markets lowered their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $3.63.

Lucid Diagnostics Stock Up 2.3 %

LUCD stock traded up $0.02 during mid-day trading on Tuesday, reaching $0.82. The company had a trading volume of 567,140 shares, compared to its average volume of 239,096. The stock’s 50-day simple moving average is $0.90 and its two-hundred day simple moving average is $0.84. The stock has a market capitalization of $48.58 million, a P/E ratio of -0.72 and a beta of 1.42. Lucid Diagnostics has a one year low of $0.63 and a one year high of $1.58.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.